Home › Osteosarcoma › North Carolina › Durham
Osteosarcoma clinical trials in Durham, NC
5 studies for Osteosarcoma are looking for participants at sites in and around Durham (within about 30 miles). Open a study to see who can join and how to contact the study team.
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
RecruitingPhase 2
- Duke University Medical Center, Durham
The CATSINDO Trial - Clinical and Translational Study in Newly Diagnosed Osteosarcoma
RecruitingPhase 2
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi away
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
RecruitingPhase 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi away
SPEARHEAD-3 Pediatric Study
RecruitingPhase 1/2
- Duke University School of Medicine, Durham
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
RecruitingPhase 1
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi away
Osteosarcoma trials in other cities
- Memphis, TN10 studies
- St. Louis, MO10 studies
- Atlanta, GA10 studies
- Boston, MA9 studies
- Mountain View, CA8 studies
- Houston, TX7 studies
- Chicago, IL7 studies
- Birmingham, AL7 studies
- Los Angeles, CA7 studies
- Tampa, FL6 studies
- Aurora, CO6 studies
- Washington, DC6 studies
Other studies in Durham
- Breast Cancer63 studies
- Cancer (all types)59 studies
- Non-Small Cell Lung Cancer39 studies
- Multiple Myeloma37 studies
- Metastatic Cancer33 studies
- Acute Myeloid Leukemia33 studies
- Lung Cancer32 studies
- Prostate Cancer32 studies
- Colorectal Cancer28 studies
- Chronic Lymphocytic Leukemia27 studies
- Ovarian Cancer27 studies
- Heart Failure26 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.